Shares of Amedisys (AMED +17%) jump on a 5x surge in volume after it updated its Q2 guidance this morning. The company expects revenues of $300M - 305M and EPS from continuing ops of $0.15 - 0.20. This represents a significant turnaround from Q1's operating loss.

Management attributes its improved performance to healthier gross margins and lower expenses pursuant to it plans to close/consolidate care centers and right-size admin costs.

The company remains cautious on its full-year outlook due to the seasonality of the business and the early-stage nature of some of its performance initiatives.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs